Discovery of PF-05212384/PKI-587: A phase 2 clinical PI3K/mTOR inhibitor

被引：0
|
作者：
Dehnhardt, Christoph M. [1 ]
Venkatesan, Aranapkam M. [1 ]
Delos Santos, Efren [1 ]
Kaloustian, Semiramis Ayral [1 ]
Broojimans, Natasja [1 ]
Hollander, Irwin [2 ]
Chen, Zecheng [1 ]
Lucas, Judy [1 ]
Mallon, Robert [2 ]
Verheijen, Jeroen [1 ]
Zask, Arie [1 ]
Khafizofa, Gulnaz [1 ]
Bursavich, Matt [2 ]
Richard, David [1 ]
Mansour, Tarek [1 ]
机构：
[1] Pfizer, Pearl River, NY 10965 USA
[2] Wyeth, Pearl River, NY 10965 USA
来源：
ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY | 2014年 / 248卷
关键词：
D O I：
暂无
中图分类号：
O6 [化学];
学科分类号：
0703 ;
摘要：
287-MEDI
引用
收藏
页数：1
相关论文
共 50 条
  • [41] Discovery and research of a novel dual PI3K/mTOR inhibitor, DS-7423
    Shiose, Yoshinobu
    JOURNAL OF PHARMACOLOGICAL SCIENCES, 2013, 121 : 48P - 48P
  • [42] Pharmacodynamic biomarker evaluation in phase I clinical trials of selective PI3K and PI3K/mTOR inhibitors
    Nakanishi, Yoshito
    Spoerke, Jill M.
    Derynck, Mika
    Lauchle, Jennifer O.
    Koeppen, Hartmut
    Fredrickson, Jill
    Ware, Joseph
    Hampton, Garret
    Yan, Yibing
    Lackner, Mark R.
    MOLECULAR CANCER THERAPEUTICS, 2015, 14 (07)
  • [43] Discovery of an irreversible PI3Kα-specific Inhibitor
    Qiao, Lixin
    Nacht, Mariana
    Sheets, Michael P.
    St Martin, Thia
    Labenski, Matthew
    Mazdiyasni, Hormoz
    Zhu, Zhendong
    Chaturvedi, Prasoon
    Bhavsar, Deepa
    Niu, Deqiang
    Westlin, William
    Petter, Russell
    Singh, Juswinder
    CANCER RESEARCH, 2011, 71
  • [44] The discovery of the potent and selective PI3K/mTOR dual inhibitor PF-04691502 through structure-based drug design
    Cheng, Henry
    Bagrodia, Shubha
    Bailey, Simon
    Bhumalkar, Dilip
    Dress, Klaus
    Edwards, Martin
    Gehring, Michael R.
    Guo, Lisa
    Hoffman, Jacqui
    Hu, Qiyue
    Huang, Xiaojun
    Johnson, Catherine
    Johnson, Ted O.
    Kania, Robert
    Knighton, Daniel R.
    Phuong Le
    Li, Haitao
    Li, Samuel
    Liu, Kevin
    Liu, Zhengyu
    Marx, Matthew A.
    Nambu, Mitch
    Ninkovic, Sacha
    Nowlin, Dawn
    Pairish, Mason
    Pannifer, Andrew
    Plewe, Michael
    Rodgers, Caroline
    Smith, Graham
    Sun, Shaoxian
    Khanh Tran
    Wang, Hai
    Zbieg, Jason
    Zhu, Peter
    CANCER RESEARCH, 2010, 70
  • [45] Discovery of the Highly Potent PI3K/mTOR Dual Inhibitor PF-04979064 through Structure-Based Drug Design
    Cheng, Hengmiao
    Li, Chunze
    Bailey, Simon
    Baxi, Sangita M.
    Goulet, Lance
    Guo, Lisa
    Hoffman, Jacqui
    Jiang, Ying
    Johnson, Theodore Otto
    Johnson, Ted W.
    Knighton, Daniel R.
    Li, John
    Liu, Kevin K. -C.
    Liu, Zhengyu
    Marx, Matthew A.
    Walls, Marlena
    Wells, Peter A.
    Yin, Min-Jean
    Zhu, Jinjiang
    Zientek, Michael
    ACS MEDICINAL CHEMISTRY LETTERS, 2013, 4 (01): : 91 - 97
  • [46] PF-04691502, a Potent and Selective Oral Inhibitor of PI3K and mTOR Kinases with Antitumor Activity
    Yuan, Jing
    Mehta, Pramod P.
    Yin, Min-Jean
    Sun, Shaoxian
    Zou, Aihua
    Chen, Jeffrey
    Rafidi, Kristina
    Feng, Zheng
    Nickel, Jeffrey
    Engebretsen, Jon
    Hallin, Jill
    Blasina, Alessandra
    Zhang, Eric
    Nguyen, Leslie
    Sun, Minghao
    Vogt, Peter K.
    McHarg, Aileen
    Cheng, Hengmiao
    Christensen, James G.
    Kan, Julie L. C.
    Bagrodia, Shubha
    MOLECULAR CANCER THERAPEUTICS, 2011, 10 (11) : 2189 - 2199
  • [47] Evaluation of a Dual PI3K/mTOR Inhibitor PF-04691502 against Bladder Cancer Cells
    Shang, Xiaosong
    Na, Xinyu
    Wang, Lei
    Yang, Zhiqin
    Ren, Pengpeng
    EVIDENCE-BASED COMPLEMENTARY AND ALTERNATIVE MEDICINE, 2022, 2022
  • [48] Evaluation of a Dual PI3K/mTOR Inhibitor PF-04691502 against Bladder Cancer Cells
    Shang, Xiaosong
    Na, Xinyu
    Wang, Lei
    Yang, Zhiqin
    Ren, Pengpeng
    EVIDENCE-BASED COMPLEMENTARY AND ALTERNATIVE MEDICINE, 2022, 2022
  • [49] Discovery of CT365, a highly potent inhibitor of PI3K and mTOR, for cancer treatment
    Xi, Ning
    Wu, Yanjun
    Wang, Tingjin
    Wang, Heng
    Li, Zhiyong
    Meng, Qingwei
    Li, Jing
    Wang, Zhaohe
    Zhang, Yingjun
    CANCER RESEARCH, 2015, 75
  • [50] A randomized phase II study (B2151005) of the intravenous phosphatidylinositol 3-kinase (PI3K)/mammalian target of rapamycin (mTOR) inhibitor PF-05212384 plus irinotecan versus cetuximab plus irinotecan in patients with wild-type KRAS metastatic colorectal cancer (mCRC).
    Tabernero, Josep
    Braga, Nicoletta
    Davis, Craig
    Gollerkeri, Ashwin
    Pierce, Kristen
    Suzuki, Mie
    Vermette, Jennifer
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
12345